Frislid K, Berg M, Hansteen V, Lunde P K
Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):433-8. doi: 10.1007/BF00606561.
The acetylation of procainamide and sulfadimidine has been measured simultaneously in plasma and urine in 20 healthy human volunteers by a specific G.L.C. method, after single and multiple oral dral doses of procainamide retard tablets. A distinct bimodality (9 rapid and 11 slow acetylators) was apparent from the concentrations of procainamide and N-acetylprocainamide both in urine and plasma, which was in complete agreement with data about sulfadimidine acetylation. The influence of acetylator phenotype on the relative concentrations of procainamide and N-acetylprocainamide in plasma as cn 5 additional healthy subjects after a single oral dose of procainamide. The present results show that acetylator phenotype can now be determined using procainamide as the test substance, and for this purpose multiple doses offer hardly any advantage over a single dose of the drug. However, because the separation between rapid and slow acetylators is less pronounced for procainamide than for sulfadimidine, precise criteria must be established for the conditions of the test, and the influence of diseases, such as renal insufficiency, should be taken into consideration.
采用特定的气相色谱法,在20名健康志愿者单次及多次口服普鲁卡因胺缓释片后,同时测定了血浆和尿液中普鲁卡因胺和磺胺二甲嘧啶的乙酰化情况。从尿液和血浆中普鲁卡因胺和N - 乙酰普鲁卡因胺的浓度来看,明显呈现出双峰模式(9名快速乙酰化者和11名缓慢乙酰化者),这与磺胺二甲嘧啶乙酰化的数据完全一致。在另外5名健康受试者单次口服普鲁卡因胺后,研究了乙酰化者表型对血浆中普鲁卡因胺和N - 乙酰普鲁卡因胺相对浓度的影响。目前的结果表明,现在可以使用普鲁卡因胺作为测试物质来确定乙酰化者表型,并且在此方面,多次给药与单次给药相比几乎没有任何优势。然而,由于普鲁卡因胺快速和缓慢乙酰化者之间的区分不如磺胺二甲嘧啶明显,因此必须为测试条件建立精确的标准,并且应考虑诸如肾功能不全等疾病的影响。